Research Shows CBD Can Treat GVHD

November 27, 2019 16:00:38

Graft versus host disease (GVHD) is a complication that occurs when donor bone marrow or stem cells attack the recipient. The donor cells see the host cells as foreign and attack them. It can range from mild to life-threatening in severity. Last week, Kalytera Therapeutics Inc. announced their research, reported in two peer-reviewed articles published in Blood, a medical journal published by the American Society of Hematology, about CBD’s ability to help manage GVHD.

One article explored the case of a 35-year-old patient who, after a bone marrow transplant, developed a particularly aggressive skin variant of GVHD that’s difficult to manage and carries a poor prognosis. He was treated with a cannabinoid solution and within three months, there was a definite improvement, so much so that he was discontinued from other pharmaceuticals. Two years after the transplant, most of his skin issues had dwindled down to mild itchiness and flakiness.

The second article talked about how the endocannabinoid system can be manipulated to mitigate GVHD. The endocannabinoid system (ECS) is a peripheral nervous system responsible for regulating sleep, appetite, mood, and memory. It is comprised of cannabinoid (molecules quite similar to the cannabinoids in cannabis that are produced by your body), receptors and enzymes.

To signal that the endocannabinoid system needs to take some sort of action, the cannabinoids bind to the receptors. There are two main receptors; CB1 receptors mainly found in the central nervous system, and CB2 receptors, found in the peripheral nervous system, especially the immune cells. The CB2 receptors were central to Kalytera’s research.

The study found that signaling through the CB2 receptors mitigates the severity of GVHD and that CBD also inhibits graft versus host reactivity. “Our laboratory findings, as well as the research reported in the peer-reviewed articles, point to the potentially important role of CBD in the prevention and treatment of GVHD,” says Robert Farrell, Kalytera’s President and CEO.

The company holds two exclusive US-issued patents covering the use of CBD in the prevention and treatment of GVHD, and it is currently waiting for its application for an EU license to be passed. Kalytera has also obtained four orphan drug designations for the treatment and prevention of GVHD in Europe and the U.S.

The company is looking to position itself as the leading developer of CBD medicines for a range of important unmet medical needs, focusing on GVHD.

CBD industry watchers are convinced that the success in showing that CBD can help in treating and even preventing GVHD is good news to sector players like SinglePoint Inc. (OTCQB: SING) and Dama Financial since it brings good vibes to the whole industry.

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.